Want to see GSK full AI Analyst Report?
GSK Stock Chart & Stats
$51.35
$0.61(1.20%)
At close: 4:00 PM EDT
$51.35
$0.61(1.20%)
Day’s Range― - ―
52-Week Range$38.62 - $61.70
Previous CloseN/A
Volume5.86M
Average Volume (3M)3.82M
Market Cap
$102.51B
Enterprise Value$125.93K
Total Cash (Recent Filing)$3.09B
Total Debt (Recent Filing)$18.13B
Price to Earnings (P/E)15.6
Beta0.31
Next Earnings
Oct 28, 2026EPS Estimate
1.37Next Dividend Ex-DateN/A
Dividend Yield3.57%
Share Statistics
EPS (TTM)2.40
Shares Outstanding2,022,705,600
10 Day Avg. Volume4,611,242
30 Day Avg. Volume3,819,816
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$68.55Price Target Upside33.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)4.77
Revenue Forecast (FY)$45.35B
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.
Pipeline DevelopmentKey launches and pipeline catalysts over the next 12 months should build confidence in GSK's £40B sales target by 2031, the majority of which is from on-market products.
Product DevelopmentThe launch of depemokimab is another inflection point given the opportunity biologics have to further penetrate the respiratory market.
Product LaunchesBlenrep's U.S. PDUFA and commercial launches will be key factors in achieving GSK's target.
Bears Say
External ChallengesDespite the uncertain external environment, GSK is confident in its ability to navigate challenges.
Sales Target ConcernsGSK noted the majority (50%+) of its 2031 sales target of £40B is from products already on the market.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $38.62 and its highest was $61.70 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $102.51B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 28, 2026 which is in 76 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 28, 2026. The company reported $1.342 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.102.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.452 which represents an annual dividend yield of 3.57%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.37.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,022,705,600 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.342 in its last earnings report, beating expectations of $1.24. Following the earnings report the stock price went up 3.328%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$68.55 (33.50% Upside)
$68.55 (33.50% Upside)
Blogger Sentiment
Bullish
GSK Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 10.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.29%
12-Months-Change
Fundamentals
Return on Equity
3.57%
Trailing 12-Months
Asset Growth
0.91%
Trailing 12-Months
Company Description
GlaxoSmithKline
GlaxoSmithKline plc (GSK) is a global biopharmaceutical company focused on researching, developing, manufacturing, and commercializing prescription medicines and vaccines. The company’s core business spans specialty and primary-care medicines across areas such as respiratory/immunology and inflammation, infectious diseases, HIV (through its majority ownership interest in ViiV Healthcare), and oncology, alongside a global vaccines portfolio. GSK sells its products to healthcare providers, pharmacies, governments, and other healthcare organizations across multiple geographies.
GSK Company Deck
GSK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone: strong operational execution produced record infrastructure results, marked improvements in marketing, accretive M&A (Chauvin), improved throughput and cash flow, and concrete balance sheet and cost-savings actions. Challenges were primarily industry-wide and temporary — export volatility, vessel/freight constraints, short-term storage market dynamics, and leverage that management expects to normalize in early 2027. Management expressed confidence in organic growth opportunities and reiterated targets for deleveraging and sustainable cost savings.View all GSK earnings summariesGSK Stock 12 Month Forecast
Average Price Target
$68.55
▲(33.50% Upside)
Technical Analysis
Ownership Overview
―
Insiders
6.17% Mutual Funds
3.34% Other Institutional Investors
90.14% Public Companies and Individual Investors